<DOC>
	<DOCNO>NCT00002829</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell , may effective treatment lymphoma . Bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy use kill cancer cell . PURPOSE : Phase II trial study effectiveness bone marrow transplantation treat patient recurrent residual low-grade lymphoma .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Examine potential role high dose etoposide , cyclophosphamide , total body irradiation bone marrow transplantation patient high risk disease progression . II . Determine value monitor quality remission PCR assessment BCl-2 . III . Evaluate efficacy alpha interferon patient evidence residual recurrent lymphoma . IV . Evaluate efficacy bone marrow purge PCR assessment BCl-2 . OUTLINE : Patients receive brief 2-3 cycle intensive chemotherapy achieve minimum disease state . Etoposide administer intravenously day -8 . Cyclophosphamide infuse intravenously 2 hour daily day -7 -6 . Patients receive mesna begin 1 hour initiation cyclophosphamide treatment . Total body irradiation receive day -4 , -3 , -2 , -1 . On day 0 allogeneic autologous bone marrow infuse intravenously . Patients residual recurrent lymphoma receive interferon alpha daily . PROJECTED ACCRUAL : 35 allogeneic 40 autologous patient expect enrolled .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven low grade lymphoma follow setting : Consolidation newly diagnose stage IV highrisk patient 69 month intensive conventional dose chemotherapy involve doxorubicin High risk define &gt; =5 cm adenopathy &gt; =2 extranodal sit diagnosis , male &gt; =5 cm adenopathy &gt; 20 % marrow infiltrate diagnosis ) Failure achieve CR within 6 month newly diagnose patient intensive doxorubicin treatment Relapse patient sensitive doxorubicin ESHAP chemotherapy Patients resistant chemotherapy failure ( allogeneic BMT ) Patients HLAidentical sibling donor eligible allogeneic bone marrow transplantation ; patient eligible autologous marrow transplantation Bone marrow must complete near complete remission ( &lt; 15 % malignant cell ) autologous transplant patient PATIENT CHARACTERISTICS : Age : 15 60 year Performance Status : Zubrod 02 Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 2.0 mg/dL Cardiovascular : Cardiac ejection fraction least 50 % Pulmonary : DLCO least 50 % Other : No concomitant severe medical illness No psychosis PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior chemotherapy allow Endocrine therapy : Not specify Radiotherapy : No prior extensive radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma</keyword>
	<keyword>mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>